Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (251-260 of 493) with videos related to

Pageof 50
Sort By:
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2006
Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)Amélie Servettaz, Mathieu C Tamby, Philippe Guilpain, et al.
The Journal of Rheumatology|November 18, 2009
Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional studyOlivier Meyer, Luc De Chaisemartin, Pascale Nicaise-Roland, et al.
Presse Medicale (Paris, France : 1983)|November 23, 2007
[Management of digital ulcers from systemic scleroderma]Camille Francès, Yannick Allanore, Jean Cabane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2019
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic SclerosisVincent Sobanski, Jonathan Giovannelli, Yannick Allanore, et al.
Scientific Reports|February 28, 2025
Inflammatory and angiogenic serum profile of refractory rheumatoid arthritisManon Lesturgie-Talarek, Virginie Gonzalez, Alice Combier, et al.
Expert Review of Clinical Immunology|October 20, 2020
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patientsFrancesco Benvenuti, Elisabetta Zanatta, Jérôme Avouac, et al.
The Lancet. Rheumatology|January 24, 2024
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trialsAnna-Maria Hoffmann-Vold, Elizabeth R Volkmann, Yannick Allanore, et al.
Rheumatology (Oxford, England)|April 2, 2011
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosisJérôme Avouac, Maud Clemessy, Jörg H Distler, et al.
Annals of the Rheumatic Diseases|August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertensionJerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Pageof 50

Showing results (251-260 of 493) with videos related to

Sort By:
Pageof 50
European Respiratory Review : an Official Journal of the European Respiratory Society|July 15, 2024
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosisElizabeth R Volkmann, Christopher P Denton, Martin Kolb, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2006
Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)Amélie Servettaz, Mathieu C Tamby, Philippe Guilpain, et al.
The Journal of Rheumatology|November 18, 2009
Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional studyOlivier Meyer, Luc De Chaisemartin, Pascale Nicaise-Roland, et al.
Presse Medicale (Paris, France : 1983)|November 23, 2007
[Management of digital ulcers from systemic scleroderma]Camille Francès, Yannick Allanore, Jean Cabane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2019
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic SclerosisVincent Sobanski, Jonathan Giovannelli, Yannick Allanore, et al.
Scientific Reports|February 28, 2025
Inflammatory and angiogenic serum profile of refractory rheumatoid arthritisManon Lesturgie-Talarek, Virginie Gonzalez, Alice Combier, et al.
Expert Review of Clinical Immunology|October 20, 2020
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patientsFrancesco Benvenuti, Elisabetta Zanatta, Jérôme Avouac, et al.
The Lancet. Rheumatology|January 24, 2024
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trialsAnna-Maria Hoffmann-Vold, Elizabeth R Volkmann, Yannick Allanore, et al.
Rheumatology (Oxford, England)|April 2, 2011
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosisJérôme Avouac, Maud Clemessy, Jörg H Distler, et al.
Annals of the Rheumatic Diseases|August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertensionJerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Pageof 50